Clinical trials
-
NSCLC – Theranostics – 177Lu-RAD204
Read more: NSCLC – Theranostics – 177Lu-RAD204Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium -177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Non-small Cell Lung Cancer
-
Ovarian cancer – LY4170156 – ADC Targeting Folate Receptor
Read more: Ovarian cancer – LY4170156 – ADC Targeting Folate ReceptorA First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor a -Expressing Tumor Cells, in Participants with Selected Advanced Solid Tumors
-
Advanced Solid Tumours – Anti-HER3 ADC
Read more: Advanced Solid Tumours – Anti-HER3 ADCFirst-in-Human, Phase 1 Study of AMT-562, an Anti-HER3 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
-
Urothelial Cancer – BT8009 Monotherapy or Combo
Read more: Urothelial Cancer – BT8009 Monotherapy or ComboA Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer
-
Advanced Solid Tumors – BG-C477 – High CEA
Read more: Advanced Solid Tumors – BG-C477 – High CEAA Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors
-
Gastric and Solid Tumours – AB598
Read more: Gastric and Solid Tumours – AB598A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
-
Breast cancer – Metastatic Her2 positive
Read more: Breast cancer – Metastatic Her2 positiveJZP598-303: A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment.